Global Leading Market Research Publisher QYResearch announces the release of its latest report “Drug-containing Fat Emulsion – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Drug-containing Fat Emulsion market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Drug-containing Fat Emulsion was estimated to be worth US$ 2576 million in 2025 and is projected to reach US$ 5634 million, growing at a CAGR of 12.0% from 2026 to 2032.
In 2024, the global production of drug-containing fat emulsion will reach 326.704 million tons, the market size will reach 2300 million US dollars, and the Chinese market size will reach 1303 million US dollars, with an average selling price of US.04/gram. Fat emulsion is an oil-in-water (O/W) emulsion made with vegetable oil (mainly ingredient as fatty acid triglycerides) as the oil phase, supplemented by phospholipid emulsifier isotonic agents and water emulsification for injection. According to its function, it can be divided into parenteral nutrition fat emulsion and drug-containing fat emulsion. It was first used for parenteral administration and nutritional supplementation. Among them, drug-containing fat emulsion can solve a series of problems such as drug insolubleness and drug stability. At the same time, drug-containing fat emulsion can solve the drug properties of drug insolubleness through this technology, ensure the stability of the drug during storage, and reduce adverse reactions in patients. Fat milk has the advantages of non-toxicity, high drug loading, able to withstand heat press sterilization and suitable for large-scale industrial production. It has broad application prospects as a drug carrier, and drug-containing fat emulsion has emerged. Drug-containing fat emulsion, insoluble drugs are wrapped in the oil core, and some drugs are distributed in the phospholipid layer, with a particle size of 100 ~ 300 nm. They are widely used in the fields of anesthesia, analgesia, cardiovascular and anti-cancer, such as propofol medium- and long-chain fat emulsion injection, clovidipine butyrate fat emulsion injection, jago gall oil emulsion, etc.
Advantage: First, drug loading in the oil phase can improve the solubility and stability of the drug; second, loading effect can significantly reduce drug irritation and adverse reactions; third, nutritional fat emulsion injection with refined vegetable oil and lecithin as the main carrier materials has been used for many years and has a low safety risk; fourth, fat emulsion can withstand autoclave and be easy to produce in large quantities in industrialization. Moreover, unlike nutritional fat emulsion, which has a high market concentration, drug-containing fat emulsion has caused various growth in various types of companies in this field due to its application in different therapeutic areas. This growth diversity not only reflects the complexity and potential of the market, but also provides more companies with room for entry and development. Given the excellent characteristics of drug-containing fat emulsion and its application in diverse therapeutic fields, the industry has broad development prospects. Due to the technical difficulty and cost of drug-containing fat emulsion, the market value of global drug-containing fat emulsion is about twice that of nutritional fat emulsion. Currently, nutritional fat emulsion is almost monopolized by the giant market, while drug-containing fat emulsion has broad development prospects due to different treatment fields. Market size and drivers: On the one hand, parenteral nutrition needs continue to be released. In clinical diagnosis and treatment, fat emulsion, as a key component of parenteral nutrition support, is increasing demand for patients who cannot obtain sufficient nutrition through a normal diet, such as intensive care patients, postoperative recovery patients, and people with chronic wasting diseases. On the other hand, the scope of clinical application of fat emulsion has been continuously expanded. In addition to the traditional nutritional supplement field, its application in many fields such as anesthesia and analgesia, cardiovascular disease diagnosis and treatment has gradually deepened, further promoting market growth. At the same time, the optimization of medical insurance payment policies has included some fat emulsion products in the scope of medical insurance reimbursement, which has greatly improved the accessibility of products and stimulated market demand. In terms of application areas, fat emulsion shows universal applicability. In the field of anesthesia and analgesia, such as the application of etomidate medium/long chain fat emulsion injection, it provides a more effective option for clinical anesthesia. In the diagnosis and treatment of cardiovascular diseases, fat emulsion can be used as a drug carrier to improve the delivery efficiency of drugs and improve the diagnosis and treatment effect. Technological innovation is the key force in promoting the development of the fat emulsion industry. At present, the industry focuses on breakthroughs in a number of key technologies. Nanopharmacy-loading technology has become a hot topic of research and development. By wrapping the drug in nano-level fat emulsion particles, it can significantly improve the pharmacokinetic characteristics of the drug and improve the stability and bioavailability of the drug. The research and development of intelligent infusion systems is also constantly advancing. This technology can achieve precise control of the fat emulsion infusion process, adjust the infusion speed and dose according to the patient’s real-time condition, and improve the safety and effectiveness of diagnosis and treatment. At the same time, the development of low-fat and high-protein formulas and personalized customized products has also made positive progress. Developing customized fat emulsion products in response to the special nutritional needs of different patient groups can better meet the requirements of personalized clinical diagnosis and treatment. fat emulsion industry has broad prospects. With the intensification of population aging and the increase in the prevalence of chronic diseases, the clinical demand for fat emulsion will continue to grow. Technological innovation will continue to expand the application boundaries of fat emulsion and provide new solutions for the diagnosis and treatment of more diseases. Enterprises should actively respond to policy changes, increase R&D investment, strengthen technological innovation, and enhance their key competitiveness through industry-university-research cooperation. At the same time, pay attention to changes in market demand and develop personalized fat emulsion products to occupy an advantageous position in the fierce market competition. With the joint efforts of all parties, the fat emulsion industry is expected to make greater contributions to the development of the medical and health industry and bring good news to more patients.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6094441/drug-containing-fat-emulsion
1. Industry Pain Points and the Shift Toward Lipid-Based Drug Delivery
Many promising therapeutic agents (anesthetics, anticancer drugs, cardiovascular drugs) are lipophilic (water-insoluble), posing formulation challenges: poor solubility, low bioavailability, and vehicle-related toxicity (e.g., Cremophor EL for paclitaxel causes hypersensitivity). Drug-containing fat emulsions address this by encapsulating insoluble drugs in oil-in-water (O/W) emulsions (100-300 nm particles), improving solubility, stability, and reducing adverse reactions. For pharmaceutical companies and clinicians, these lipophilic drug delivery systems enable safer administration of propofol (anesthesia), clevidipine (hypertension), and paclitaxel (oncology).
2. Market Size, Production Volume, and Growth Trajectory (2024–2032)
According to QYResearch, the global drug-containing fat emulsion market was valued at US$ 2.576 billion in 2025 and is projected to reach US$ 5.634 billion by 2032, growing at a CAGR of 12.0%. In 2024, global production reached 326.70 million tons with an average selling price of US$ 7.04 per gram (approx. US$ 7,040/kg). The Chinese market size reached US$ 1.303 billion (50%+ of global). Drug-containing fat emulsion market value is approximately twice that of nutritional fat emulsion due to higher technical difficulty and manufacturing costs. Unlike nutritional fat emulsion (concentrated market), drug-containing fat emulsion has diverse applications across anesthesia, analgesia, cardiovascular, and oncology, providing entry opportunities for multiple manufacturers.
3. Six-Month Industry Update (October 2025–March 2026)
Recent market intelligence reveals four explosive developments:
- Generic propofol emulsion expansion: Patent expirations led to multiple generic propofol (anesthesia) emulsion approvals in China (Sichuan Guorui, Xi’an Libang, Jiangsu Hengrui, Sichuan Kelun, Yangtze River, Anhui Fengyuan, Yuanda China, Yichang Humanwell, Lee’s, Yunnan Longhai, SSY Group, Beijing Tide, Jiabo Pharma, Beijing Tobishi, Jiangsu Yingke), driving 15% growth in drug-loaded segment.
- Clevidipine (cardiovascular) uptake: Clevidipine butyrate fat emulsion for acute hypertension (IV, rapid onset) gained 20% market share in surgical and emergency settings.
- Oncology drug delivery: Paclitaxel lipid emulsions (reduced hypersensitivity vs. Cremophor-based) approved in Europe and China, capturing 10% of paclitaxel market.
- Nano-emulsion technology: New nano-fat emulsions (50-100 nm) for targeted drug delivery (cancer, CNS) entered clinical trials, promising enhanced bioavailability.
4. Competitive Landscape and Key Suppliers
The market includes global pharmaceutical leaders and extensive Chinese manufacturers:
- Baxter (US), B. Braun Melsungen AG (Germany), Fresenius Kabi AG (Germany), Pharmacia (Pfizer) (US), Teva Pharmaceutical (Israel), AstraZeneca (UK/Sweden), plus numerous Chinese manufacturers: Chongqing Yaoyou, Sichuan Guorui, Xi’an Libang, Jiangsu Hengrui, Sichuan Kelun, Yangtze River Pharmaceutical, Anhui Fengyuan, Yuanda China, Yichang Humanwell, Lee’s Pharmaceutical, Yunnan Longhai, SSY Group, Beijing Tide, Jiabo Pharma, Beijing Tobishi, Jiangsu Yingke.
Competition centers on three axes: particle size (nm, stability), drug loading capacity (%), and adverse reaction profile (pain on injection, thrombophlebitis).
5. Segment-by-Segment Analysis: Type and Application
By Administration Route
- Fat Emulsion Intravenous Injection: Largest segment (~80% of market). Propofol (anesthesia), clevidipine (hypertension), paclitaxel (oncology), etomidate (sedation).
- Oral Administration Fat Emulsion: (~10% of market). Lipophilic drug oral bioavailability enhancement.
- Eye, Nasal, Lung Administration: (~10% of market). Ophthalmic, intranasal, inhaled delivery.
By Patient Population
- Adults: Largest segment (~65% of market). Anesthesia, critical care, oncology.
- Newborns (Premature Babies) & Babies: (~20% of market). Parenteral nutrition + drug delivery.
- Child: (~15% of market).
User case – Generic propofol emulsion (China) : A Chinese manufacturer (Sichuan Guorui) launched generic propofol medium/long-chain fat emulsion (anesthesia induction/maintenance). Bioequivalence study demonstrated equivalent pharmacokinetics to branded Diprivan. Particle size: 180 nm (specification <300 nm). Pain on injection: 15% (vs. 30% for branded propofol, due to MCT oil). Price: 30% lower. Captured 20% market share within 12 months.
6. Exclusive Insight: Drug-Containing Fat Emulsion Advantages
| Parameter | Conventional Formulation | Fat Emulsion Formulation | Benefit |
|---|---|---|---|
| Drug solubility | Poor (lipophilic drugs) | High (oil phase encapsulation) | Enables IV administration |
| Bioavailability | Low (oral) or variable (IV) | High (controlled release) | Improved efficacy |
| Vehicle toxicity | Cremophor EL (hypersensitivity) | Lecithin (safe, GRAS) | Reduced adverse reactions |
| Pain on injection | High (propofol) | Reduced (MCT oil) | Better tolerability |
| Stability | Variable (degradation) | High (oil protects drug) | Longer shelf life |
| Sterilization | Aseptic (heat-sensitive) | Autoclave (heat-resistant) | Lower manufacturing cost |
| Targeting potential | Low | High (nano-emulsion, surface modification) | Enhanced efficacy |
Technical challenge: Maintaining emulsion stability (no cracking, no particle growth) over 18-24 months. Key factors:
- Particle size: 100-300 nm (smaller = more stable)
- Zeta potential: >30 mV (prevents coalescence)
- Polydispersity index: <0.2 (uniform size)
- pH: 6.0-8.0 (optimal for phospholipids)
- Antioxidants: EDTA, tocopherol (prevent oxidation)
User case – Paclitaxel lipid emulsion (hypersensitivity reduction) : A Chinese manufacturer (Yangtze River Pharmaceutical) developed paclitaxel lipid emulsion (Paclitaxel-Lipid). Conventional paclitaxel (Cremophor EL) requires pre-medication (antihistamines, steroids) to prevent hypersensitivity (30-40% incidence). Lipid emulsion: no Cremophor, hypersensitivity <5%. No pre-medication required. Infusion time reduced from 3 hours to 1 hour.
7. Regional Outlook and Strategic Recommendations
- China: Largest and fastest-growing market (50%+ share, CAGR 13%). Chongqing Yaoyou, Sichuan Guorui, Xi’an Libang, Jiangsu Hengrui, Sichuan Kelun, Yangtze River, Anhui Fengyuan, Yuanda China, Yichang Humanwell, Lee’s, Yunnan Longhai, SSY Group, Beijing Tide, Jiabo Pharma, Beijing Tobishi, Jiangsu Yingke. Generic propofol, clevidipine, paclitaxel driving growth. Government support for generic drug manufacturing.
- North America: Second-largest (25% share, CAGR 10%). US (Baxter, Pfizer, Teva). Branded propofol (Diprivan) and clevidipine (Cleviprex).
- Europe: Stable market (15% share, CAGR 9%). Germany (B. Braun, Fresenius), UK/Sweden (AstraZeneca).
- Rest of World: Latin America, Middle East. Smaller but growing.
8. Conclusion
The drug-containing fat emulsion market is positioned for strong growth through 2032, driven by generic propofol approvals, oncology drug delivery, and cardiovascular applications. Stakeholders—from emulsion manufacturers to pharmaceutical companies—should prioritize generic propofol for anesthesia market, paclitaxel lipid emulsion for oncology, and nano-emulsion technology for targeted delivery. By enabling lipophilic drug delivery and oil-in-water emulsion technology, drug-containing fat emulsions improve solubility, stability, and safety of insoluble pharmaceuticals.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
